thereof as defined herein, in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents.

In a further aspect of the present disclosure, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined herein for use in therapy.

In another aspect of the present disclosure, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined herein for use in treating pain disorders, atherosclerosis or fibrosis.

In yet another aspect of the present disclosure, there is provided a use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined herein, in the manufacture of a medicament for treating pain disorders, atherosclerosis or fibrosis.

Detailed Description

In accordance with the present invention, there is therefore provided a compound of formula (I)

3. A compound according to claim 1 or claim 2, wherein X represents an oxygen atom or -CH_2O-.

4. A compound according to any one of claims 1 to 3, wherein either m is 0, or, m is 1 or 2 and each R^2 independently represents a halogen atom or a C_1-C_6 alkyl group.

5. A compound according to any one of claims 1 to 4, wherein Y represents CH_2.

6. A compound according to any one of claims 1 to 5, wherein R^3 represents a C_1-C_3 alkyl group optionally substituted by one or more substituents as defined in claim 1.

7. A compound according to any one of claims 1 to 5, wherein R^3 represents a saturated or unsaturated 3- to 6-membered hydrocarbyl ring system optionally substituted by one or more substituents as defined in claim 1.

8. A compound according to claim 6 or claim 7, wherein the optional substituents are selected from fluorine, chlorine, hydroxyl, C_3-C_6 cycloalkyl, C_1-C_2 alkoxy, phenoxy, benzyloxy, trifluoromethyl, C_1-C_2 alkyl, and a saturated or unsaturated 3-, 4-, 5- or 6-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system itself being optionally substituted by least one substituent selected from halogen, C_1-C_2 alkyl and C_1-C_2 alkoxy.

9. A compound according to any one of the preceding claims, wherein Z represents CH_2.

10. A compound according to any one of the preceding claims, wherein either n is 0, or, n is 1 and R^4 represents a halogen atom or a C_1-C_6 alkyl or C_1-C_6 alkoxy group.

4-((4-(2-Chlorophenoxy)-*N*-(2,2-difluoroethyl)benzamido)methyl)benzoic acid,

4-((*N*-(Cyclopropylmethyl)-4-(5-fluoro-2-methoxyphenoxy)benzamido)methyl)benzoic acid,

4-((4-(4-Fluoro-2-methoxyphenoxy)-*N*-propylbenzamido)methyl)benzoic acid,

4-((4-(5-Fluoro-2-methoxyphenoxy)-*N*-propylbenzamido)methyl)benzoic acid,

4-((*N*-(Cyclopropylmethyl)-4-(3-fluoro-2-methoxyphenoxy)benzamido)methyl)benzoic acid,

4-((*N*-(Cyclopropylmethyl)-5-(2-fluorophenoxy)pyrimidine-2-carboxamido)methyl)benzoic acid,

4-((*N*-(Cyclopropylmethyl)-5-(2-methoxyphenoxy)pyrimidine-2-carboxamido)methyl)benzoic acid,

4-((5-(2-Methoxyphenoxy)-*N*-propylpyrimidine-2-carboxamido)methyl)benzoic acid,

and pharmaceutically acceptable salts thereof.

14. The compound according to claim 13, wherein the compound is 4-((N-(cyclopropylmethyl)-4-(2-fluorophenoxy)benzamido)methyl)benzoic acid.

15. A compound according to claim 13, wherein the compound is 4-((N-(cyclopropylmethyl)-4-(2-fluorophenoxy)benzamido)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 13, wherein the compound is 4-((N-(Cyclopropylmethyl)-4-(2-methoxyphenoxy)benzamido)methyl)benzoic acid.

17. A compound according to claim 13, wherein the compound is 4-((N-(Cyclopropylmethyl)-4-(2-methoxyphenoxy)benzamido)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

18. A compound according to claim 13, wherein the compound is 4-((N-(Cyclopropylmethyl)-2-fluoro-4-(2-fluorophenoxy)benzamido)methyl)benzoic acid.

19. A compound according to claim 13, wherein the compound is 4-((N-(Cyclopropylmethyl)-2-fluoro-4-(2-fluorophenoxy)benzamido)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

20. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 which comprises hydrolysing a compound of formula (II)



(II)

wherein L^1 represents a leaving group and R^1, X, m, R^2, Y, R^3, Z, n, R^4, A and B are as defined in formula (I), in the presence of a suitable base;

and optionally thereafter carrying out one or more of the following procedures:

- converting a compound of formula (I) into another compound of formula (I)
- removing any protecting groups
- forming a pharmaceutically acceptable salt.

21. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19, in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents.

22. A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19 for use in therapy.

23. A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19 for use in treating pain disorders, atherosclerosis or fibrosis.

24. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19, in the manufacture of a medicament for treating pain disorders, atherosclerosis or fibrosis.